Vise Technologies Inc. Acquires New Position in Krystal Biotech, Inc. $KRYS

Vise Technologies Inc. acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,762 shares of the company’s stock, valued at approximately $655,000.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Krystal Biotech during the second quarter worth approximately $1,554,113,000. Avoro Capital Advisors LLC boosted its holdings in shares of Krystal Biotech by 4.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after purchasing an additional 111,111 shares during the period. State Street Corp boosted its holdings in shares of Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after purchasing an additional 128,639 shares during the period. Soleus Capital Management L.P. grew its stake in Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 5.5% in the third quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock worth $94,261,000 after purchasing an additional 28,075 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,642 shares of company stock worth $16,471,923 over the last quarter. Insiders own 13.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KRYS. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. HC Wainwright raised their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, Citigroup lifted their price objective on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $365.40.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $346.58 on Monday. The stock has a 50-day moving average of $347.03 and a two-hundred day moving average of $301.54. The stock has a market cap of $10.26 billion, a PE ratio of 43.43 and a beta of 0.53. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.